source
- Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial missAstraZeneca reported that its experimental drug Wainua failed to meet its primary endpoints in a study of transthyretin amyloid cardiomyopathy (ATTR-CM). The setback raised concerns about the thera…
- Arrowhead's RNAi drug Redemplo shows safety advantage over Ionis in late-stage triglyceride trialsAt the European Society of Cardiology meeting in Munich, Arrowhead Pharmaceuticals presented new data on its RNA interference candidate Redemplo. Redemplo was evaluated in two late-stage studies i…